Vectura Group plc Directorate Change (2801A)

TIDMVEC

RNS Number : 2801A

Vectura Group plc

28 September 2020

Board Change

Chippenham, UK - 28 September 2020 : Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces that Ms Anne Whitaker is stepping down from the Board and as an Independent Non-Executive Director of Vectura. This change will take effect from 30 September 2020.

Ms. Whitaker and the Board have determined, with regret, that it is appropriate for her to step down in light of potential conflicts that could arise in the future as a result of her role of Chief Executive Officer at Aerami Therapeutics.

Bruno Angelici, Chairman of the Board, said: "I would like to thank Anne for her significant contributions to Vectura since her appointment in June 2018. On behalf of the all the Board, I wish her every success in her continuing role at Aerami Therapeutics and for the future."

Anne Whitaker added: "I have thoroughly enjoyed my role on the Board of Vectura and am very grateful to Bruno and the entire management team and Board for the opportunity. Vectura is extremely well-positioned for the future as a CDMO and I look forward to seeing the Company achieve success with partnering with pharmaceutical and biotech companies to make a difference for patients."

The Nomination Committee has initiated steps to seek an appropriate additional Independent Non-Executive Director and will take diversity matters fully into account when reviewing candidates for this appointment.

- Ends -

 
 For more information, please contact: 
 Vectura Group plc 
 David Ginivan - VP Corporate Communications 
  Elizabeth Knowles - VP Investor               [phone] 
  Relations                                      [phone] 
 Consilium Strategic Communications 
 Mary-Jane Elliott / Sue Stuart 
  / David Daley                                 [phone] 
 

Notes

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

About Aerami

Aerami Therapeutics, currently a customer of Vectura, is a biopharmaceutical company committed to developing inhaled therapies for the treatment of pulmonary arterial hypertension and other severe respiratory diseases.

For further information, please visit Vectura's website at www.vectura.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADVLBLBKLEBBL

(END) Dow Jones Newswires

September 28, 2020 05:00 ET (09:00 GMT)